Effects of depression and serotonergic antidepressants on bone: mechanisms and implications for the treatment of depression

Fernandes, Brisa S., Hodge, Jason M., Pasco, Julie A., Berk, Michael and Williams, Lana J. 2016, Effects of depression and serotonergic antidepressants on bone: mechanisms and implications for the treatment of depression, Drugs & aging, vol. 33, no. 1, pp. 21-25, doi: 10.1007/s40266-015-0323-4.

Attached Files
Name Description MIMEType Size Downloads

Title Effects of depression and serotonergic antidepressants on bone: mechanisms and implications for the treatment of depression
Author(s) Fernandes, Brisa S.ORCID iD for Fernandes, Brisa S. orcid.org/0000-0002-3797-7582
Hodge, Jason M.
Pasco, Julie A.ORCID iD for Pasco, Julie A. orcid.org/0000-0002-8968-4714
Berk, MichaelORCID iD for Berk, Michael orcid.org/0000-0002-5554-6946
Williams, Lana J.ORCID iD for Williams, Lana J. orcid.org/0000-0002-1377-1272
Journal name Drugs & aging
Volume number 33
Issue number 1
Start page 21
End page 25
Total pages 5
Publisher Springer
Place of publication Berlin, Germany
Publication date 2016-01
ISSN 1179-1969
Summary Osteoporosis is a chronic skeletal disease marked by microarchitectural deterioration of the bone matrix and depletion of bone mineral density (BMD), with a consequent increased risk for fragility fractures. It has been frequently associated with depression, which is also a chronic and debilitating disorder with high prevalence. Selective serotonin reuptake inhibitors (SSRIs), first-line agents in the pharmacological treatment of mood and anxiety disorders, have also been shown to negatively affect bone metabolism. SSRIs are the most prescribed antidepressants worldwide and a large number of persons at risk of developing osteoporosis, including older patients, will receive these antidepressants. Therefore, a proper musculoskeletal evaluation of individuals who are being targeted for or using SSRIs is a priority. The aim of this article is to review the evidence regarding the effects of depression and serotonergic antidepressants on bone and its implications for clinical care.
Language eng
DOI 10.1007/s40266-015-0323-4
Field of Research 110319 Psychiatry (incl Psychotherapy)
1115 Pharmacology And Pharmaceutical Sciences
Socio Economic Objective 920410 Mental Health
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2016, Springer
Persistent URL http://hdl.handle.net/10536/DRO/DU:30079518

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 29 times in TR Web of Science
Scopus Citation Count Cited 24 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 389 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Tue, 01 Dec 2015, 16:23:34 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.